Industry Symposia

Day 1 – 21 September 2021

10:30–11:30 Industry Symposium 2 – Otsuka

The International Patient and Provider Voice in IgA Nephropathy

Moderator: Jonathan Barratt

Dana Rizk, Vivekanand Jha, Adrian Liew, Bonnie Schneider, Gisela Delgado, Malkia White

An international roundtable discussion amongst nephrologists, patients, and a patient caregiver about living with, managing, supporting, and educating patients with IgA nephropathy. The symposium objectives include: amplifying the global voice for patients with IgA nephropathy, highlighting similarities and differences in each patient’s journey; increasing provider understanding of patients’ perspectives on living with IgA nephropathy and how these perspectives may differ internationally; understanding how providers can support patients with IgA nephropathy and which tools need to be added to their care armamentarium; identifying cross-cultural differences in IgA nephropathy diagnosis and understanding of the disease; facilitating understanding of patients’ management for IgA nephropathy, and identify current gaps in management.

15:00–15:30

Industry Symposium 6a – Novartis
Heterogeneity in IgAN: Treatment challenges and unmet needs

Chair: Smeeta Sinha

Bart Maes, Loreto Gesualdo

15:00 Welcome note
15:03 Panel discussion: Disease progression among IgAN patients with different clinical characteristics
15:15 Panel discussion: Current treatment approaches and the unmet need for optimized therapies in IgAN
15:27 Thank you and summary

An invitation to this symposium you can download here.

18:15–19:15 Industry Symposium 2 – Otsuka

The International Patient and Provider Voice in IgA Nephropathy

Moderator: Jonathan Barratt

Dana RizkVivekanand JhaAdrian LiewBonnie SchneiderGisela DelgadoMalkia White

An international roundtable discussion amongst nephrologists, patients, and a patient caregiver about living with, managing, supporting, and educating patients with IgA nephropathy. The symposium objectives include: amplifying the global voice for patients with IgA nephropathy, highlighting similarities and differences in each patient’s journey; increasing provider understanding of patients’ perspectives on living with IgA nephropathy and how these perspectives may differ internationally; understanding how providers can support patients with IgA nephropathy and which tools need to be added to their care armamentarium; identifying cross-cultural differences in IgA nephropathy diagnosis and understanding of the disease; facilitating understanding of patients’ management for IgA nephropathy, and identify current gaps in management.

19:20–20:20 Industry Symposium 1 – Calliditas

IgA nephropathy – Seeing the Bigger Picture

Jonathan Barratt: Gut-kidney pathophysiology and evidence for the role of the gut in IgAN
Richard Lafayette: Proteinuria and eGFR as endpoints and how they translate into meaningful patient outcomes

 

Day 2 – 22 September 2021

09:05–10:05 Industry Symposium 3 – Chinook

Novel Targets and Therapeutics for IgAN Management

Richard Lafayette: Pathogenesis of IgAN
Adrian Liew: Clinical rationale for a potent and selective ETA blocker for the treatment of IgAN
Jonathan Barrat: Unmet need and rationale for the development of anti-APRIL agents in IgAN

10:20–11:20 Industry Symposium 4 – Travere

The Journey to CKD in IgA Nephropathy: The Roles of Endothelin-1, Angiotensin II, and Proteinuria

Jonathan Barratt: Introduction and setting the scene
Matthias Barton: Charting the Course of CKD – Endothelin-1 and Angiotensin II: Brothers in Arms
Jürgen Floege: Signs in the Clinical Journey to CKD – Proteinuria in IgA Nephropathy
Jonathan Barratt: Changing the Course – The Evolving Treatment Landscape in IgA Nephropathy

An invitation to this symposium you can download here.

14:50–15:20 Industry Symposium 6b – Novartis

The important role of the alternative complement pathway in IgAN

Chair: Bart Maes

Lisa Willcocks

14:50 Opening remarks
14:51 Presentation: The role of the complement system, specifically the alternative pathway, in the pathogenesis of IgAN
15:03 Presentation: The current treatment paradigm in IgAN and the unmet needs
15:15 Closing remarks

An invitation to this symposium you can download here.

18:05–19:05 Industry Symposium 4 – Travere

The Journey to CKD in IgA Nephropathy: The Roles of Endothelin-1, Angiotensin II, and Proteinuria

Jonathan Barratt: Introduction and setting the scene
Matthias Barton: Charting the Course of CKD – Endothelin-1 and Angiotensin II: Brothers in Arms
Jürgen Floege: Signs in the Clinical Journey to CKD – Proteinuria in IgA Nephropathy
Jonathan Barratt: Changing the Course – The Evolving Treatment Landscape in IgA Nephropathy

An invitation to this symposium you can download here.

19:10–20:10

Industry Symposium 3 – Chinook
Novel Targets and Therapeutics for IgAN Management

Richard Lafayette: Pathogenesis of IgAN
Adrian Liew: Clinical rationale for a potent and selective ETA blocker for the treatment of IgAN
Jonathan Barrat: Unmet need and rationale for the development of anti-APRIL agents in IgAN

 

Day 3 – 23 September 2021

09:05–10:05 Industry Symposium 5 – Omeros

Emerging Evidence on the Role of Lectin Pathway Inhibition in the Management of IgAN

Objective: To enhance awareness about the pathophysiology of IgAN and educate on the role of the lectin pathway of complement using emerging clinical evidence.

Vladimir Tesar: IgAN Clinical Review: Pathophysiology and Treatment Landscape
Richard Lafayette: Mechanism and Evidence of MASP-2 Inhibition in IgAN: Racial Differences in Lectin Pathway Inhibition
Hong Zhang: Mechanism and Evidence of MASP-2 Inhibition in IgAN: Racial Differences in Lectin Pathway Inhibition (Part 2)
Jonathan Barratt: Emerged Clinical Data from Phase 2 Interim Analysis and Description of Phase 3 ARTEMIS-IGAN Trial

An invitation to this symposium you can download here.

14:35–15:35 Industry Symposium 5 – Omeros

Emerging Evidence on the Role of Lectin Pathway Inhibition in the Management of IgAN

Objective: To enhance awareness about the pathophysiology of IgAN and educate on the role of the lectin pathway of complement using emerging clinical evidence.

Vladimir Tesar: IgAN Clinical Review: Pathophysiology and Treatment Landscape
Richard Lafayette: Mechanism and Evidence of MASP-2 Inhibition in IgAN: Racial Differences in Lectin Pathway Inhibition
Hong Zhang: Mechanism and Evidence of MASP-2 Inhibition in IgAN: Racial Differences in Lectin Pathway Inhibition (Part 2)
Jonathan Barratt: Emerged Clinical Data from Phase 2 Interim Analysis and Description of Phase 3 ARTEMIS-IGAN Trial

An invitation to this symposium you can download here.

 
 

 

CONTACT

Symposium Secretariat

GUARANT International spol. s r.o.
Českomoravská 19
190 00 Prague 9
Czech Republic

+420 284 001 444
iigann2021@guarant.cz